Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neur...
March 07 2018 - 7:00AM
ANAVEX®2-73 Extends Survival and Reduces Seizures
in an Orphan Disease Model
Anavex Life Sciences Corp. (“Anavex” or the “Company”)
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company
developing differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, Rett syndrome and other central nervous system
(CNS) diseases, today announced new data for ANAVEX®2-73 in a
genetic mouse model of Tuberous Sclerosis Complex (TSC). TSC is a
rare genetic disorder characterized by the growth of numerous
benign tumors in many parts of the body with a high incidence of
seizures. The new preclinical data demonstrate that treatment with
ANAVEX®2-73 significantly increases survival and reduces seizures.
The data will be highlighted in presentations at ASENT on March 8th
and March 9th, 2018.
“These novel, preclinical findings confirm the
potential therapeutic effect of ANAVEX®2-73 to extend survival in a
genetically-based, neurodevelopmental disease,” stated Christopher
U. Missling, PhD, President and Chief Executive Officer of Anavex.
“While our clinical focus for ANAVEX®2-73 is to progress into
advanced clinical trials for Rett syndrome, Alzheimer’s disease and
Parkinson’s disease, these data suggest that sigma-1 receptor
activation with ANAVEX®2-73 could be a common target with
widespread pharmacological benefit, including those disorders that
elicit seizures, regardless of differences in the underlying CNS
pathophysiology.”
About the StudyANAVEX®2-73 (30 mg/kg/day dosed
orally for four weeks) was assessed in a Tsc1GFAP CKO mouse model
of Tuberous Sclerosis Complex, as it possesses a behavioral profile
that mimics many aspects of the clinical manifestation. The
experiments were conducted at PsychoGenics Inc., NJ, in conjunction
with the Tuberous Sclerosis Alliance. The results indicated Tsc1
CKO mice treated with ANAVEX®2-73 showed a significant improvement
in survival compared to vehicle-treated control animals (p =
0.0008) and demonstrated a significant reduction in seizures (p
< 0.05 vs. vehicle-treated mice).
Presentation Details
Symposium
presentation: |
ANAVEX®2‐73 as a potential treatment for Rett Syndrome and other
pediatric or infantile disorders with seizure pathology |
Presenter: |
Christopher U Missling, PhD, President & Chief Executive
Officer |
Date: |
Friday,
March 9, 2018 |
Time: |
4:30 p.m.
EST |
|
|
Poster
presentation: |
ANAVEX®2-73 increases survival and reduces seizures in rare disease
model of Tuberous Sclerosis |
Time: |
Thursday,
March 8, 3:45 p.m. EST and Friday, March 9, 4:15 p.m. EST |
|
|
Location: |
Hilton
Washington D.C./Rockville Hotel, Rockville, MD |
The presentations can be accessed simultaneously with the above
presentation times at www.anavex.com.
About American Society for Experimental
Neurotherapeutics (ASENT)The American Society for
Experimental Neurotherapeutics (ASENT) is an independent non-profit
organization established in 1997 by leaders in academia,
government, advocacy and industry to facilitate the process by
which new therapies are made available to patients with
neurological disorders. Its primary goal is to encourage and
advance the development of improved therapies for diseases and
disorders of the nervous system.
ASENT engages in scientific exchanges to
encourage contacts between those involved in the discovery and
development of neurotherapeutics and to provide opportunities for
dialogue between interested groups. The society organizes
education and training and publishes a journal for healthcare
practitioners, scientists and officials participating in the
neurotherapeutics field, which serves as a forum for its members
and interested groups addressing diverse issues.
About Anavex Life Sciences Corp.Anavex Life
Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical
company dedicated to the development of differentiated therapeutics
for the treatment of neurodegenerative and neurodevelopmental
diseases including Alzheimer’s disease, other central nervous
system (CNS) diseases, pain and various types of cancer. Anavex’s
lead drug candidate, ANAVEX®2-73, recently completed a successful
Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an
orally available drug candidate that restores cellular homeostasis
by targeting sigma-1 and muscarinic receptors. Preclinical studies
demonstrated its potential to halt and/or reverse the course of
Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant,
anti-amnesic, neuroprotective and anti-depressant properties in
animal models, indicating its potential to treat additional CNS
disorders, including epilepsy. The Michael J. Fox Foundation for
Parkinson’s Research has awarded Anavex a research grant to develop
ANAVEX®2-73 for the treatment of Parkinson’s disease. The grant
fully funds a preclinical study, which could justify moving
ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71,
which targets sigma-1 and M1 muscarinic receptors, is a promising
preclinical drug candidate demonstrating disease-modifying activity
against the major hallmarks of Alzheimer’s disease in transgenic
(3xTg-AD) mice, including cognitive deficits, amyloid and tau
pathologies. In preclinical trials, ANAVEX®3-71 has shown
beneficial effects on neuroinflammation and mitochondrial
dysfunction. Further information is available at www.anavex.com.
You can also connect with the company on Twitter, Facebook and
LinkedIn.
Forward-Looking StatementsStatements in this
press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks set forth in the Company’s
most recent Annual Report on Form 10-K filed with the SEC. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp. Research & Business Development
Toll-free: 1-844-689-3939 Email: info@anavex.com
Investors & Media:Clayton Robertson The Trout Group (646)
378-2900 crobertson@troutgroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024